GlassScriptPhysician profile
Jesse J Licuanan
NPI 1396795514
$2,037.28
in general payments reported to CMS, 2019-2025
26 companies · $246 in 2025
The $246 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $349 · 2020: $343 · 2021: $137 · 2022: $148 · 2023: $366 · 2024: $449 · 2025: $246.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,061.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,060.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $278.05 | 2019-2022 | |
| Biotronik INC. | $271.56 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $156.99 | 2020-2025 | Breztri, Farxiga, Airsupra |
| Novo Nordisk INC | $131.38 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Dexcom, INC. | $127.18 | 2022-2023 | Dexcom G6 Transmitter |
| Pfizer INC. | $122.43 | 2020-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $120.12 | 2024-2025 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $115.81 | 2023-2025 | |
| Lucid Diagnostics INC. | $68.34 | 2023-2024 | |
| Boston Scientific Corporation | $64.88 | 2023-2025 | Wavewriter Alpha Prime 16, General - Pain Management |
| Amgen INC. | $61.66 | 2024-2025 | Krystexxa, Repatha |
| Lilly USA, LLC | $61.59 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $59.78 | 2021-2024 | |
| Exact Sciences Corporation | $56.40 | 2023-2024 | Cologuard Collection Kit |
| Gilead Sciences, INC. | $52.38 | 2019-2020 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $47.10 | 2023-2024 | Myrbetriq, Veozah |
| Mylan Specialty L.P. | $44.95 | 2019 | |
| Abiomed | $31.71 | 2025 | |
| Edwards Lifesciences Corporation | $29.54 | 2023 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Medtronic, INC. | $26.64 | 2024 | Kyphon Express II Kyphopak Tray |
| Linus Health, INC. | $24.40 | 2024 | Core Cognitive Evaluation |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $22.17 | 2024 | Xifaxan |
| Seqirus USA INC | $17.82 | 2024 | Fluad, Flucelvax |
| Bausch Health US, LLC | $15.89 | 2024 | Aplenzin |
| Philips North America LLC | $14.88 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $13.63 | 2023 | Eliquis |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jesse Licuanan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.